文献速递淋巴瘤

早期霍奇金淋巴瘤PET导向治疗后化疗与放疗的心血管疾病预测风险

Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma.
PubMed 文献 · J Clin Oncol · 2021-08-13

基于英国NCRI RAPID试验中144例PET阴性早期霍奇金淋巴瘤患者,预测化疗和累及野放疗的30年绝对心血管风险。平均心脏剂量4.0 Gy,双侧颈总动脉平均剂量21.5 Gy;平均预测30年放疗相关心血管超额死亡0.56%,超额发病6.24%。多数患者超额风险较小,但少数接受高剂量照射者可考虑先进放疗技术或省略放疗。

要点

  • PET阴性ES-HL患者放疗后30年心血管超额死亡平均0.56%,67%患者低于0.5%。
  • 30年心血管超额发病平均6.24%,58%患者低于5%,24%患者超过10%。
  • 心脏疾病超额死亡平均0.42%,纵隔受累者0.79%,未受累者0.05%。

核心结论

  • 多数PET阴性早期霍奇金淋巴瘤患者预测心血管超额风险较小,放疗可能带来净获益。
  • 少数接受心血管结构高剂量照射的患者可考虑先进放疗技术降低剂量或省略放疗。
  • 治疗前个体化评估心血管及其他风险有助于PET导向治疗的个性化决策。

研究设计与样本

  • 基于英国NCRI RAPID随机试验中PET导向治疗的早期霍奇金淋巴瘤患者。
  • 纳入144例接受3周期ABVD化疗后PET阴性并接受累及野放疗的患者。
  • 结合心脏和颈动脉辐射剂量、化疗暴露与既定剂量反应关系及人群死亡率与发病率进行预测。

主要发现

  • 平均平均心脏剂量为4.0 Gy(范围0.1-24.0 Gy)。
  • 平均双侧颈总动脉剂量为21.5 Gy(范围0.6-38.1 Gy)。
  • 平均预测30年放疗相关绝对超额总体心血管死亡为0.56%(范围0.01%-6.79%),67%患者<0.5%,15%患者>1%。
  • 平均预测30年超额发病为6.24%(范围0.31%-31.09%),58%患者<5%,24%患者>10%。
  • 心脏疾病平均预测30年放疗相关绝对超额死亡为0.42%(纵隔受累0.79%,未受累0.05%),卒中为0.14%。

临床怎么用

  • 对PET阴性早期霍奇金淋巴瘤患者,治疗前应个体化评估心血管风险以指导放疗决策。
  • 对预测心血管超额风险较高的少数患者,可考虑先进放疗技术降低剂量或省略放疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The contemporary management of early-stage Hodgkin lymphoma (ES-HL) involves balancing the risk of late adverse effects of radiotherapy against the increased risk of relapse if radiotherapy is omitted. This study provides information on the risk of radiation-related cardiovascular disease to help personalize the delivery of radiotherapy in ES-HL. METHODS: We predicted 30-year absolute cardiovascular risk from chemotherapy and involved field radiotherapy in patients who were positron emission tomography (PET)-negative following three cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy within a UK randomized trial of PET-directed therapy for ES-HL. Cardiac and carotid radiation doses and chemotherapy exposure were combined with established dose-response relationships and population-based mortality and incidence rates. RESULTS: Average mean heart dose was 4.0 Gy (range 0.1-24.0 Gy) and average bilateral common carotid artery dose was 21.5 Gy (range 0.6-38.1 Gy), based on individualized cardiovascular dosimetry for 144 PET-negative patients receiving involved field radiotherapy. The average predicted 30-year radiation-related absolute excess overall cardiovascular mortality was 0.56% (range 0.01%-6.79%; < 0.5% in 67% of patients and > 1% in 15%), whereas average predicted 30-year excess incidence was 6.24% (range 0.31%-31.09%; < 5% in 58% of patients and > 10% in 24%). For cardiac disease, the average predicted 30-year radiation-related absolute excess mortality was 0.42% (0.79% with mediastinal involvement and 0.05% without) and for stroke, it was 0.14%. CONCLUSION: Predicted excess cardiovascular risk is small for most patients, so radiotherapy may provide net benefit. However, for a minority of patients receiving high doses of radiation to cardiovascular structures, it may be preferable to consider advanced radiotherapy techniques to reduce doses or to omit radiotherapy and accept the increased relapse risk. Individual assessment of cardiovascular and other risks before treatment would allow personalized decision making about radiotherapy in ES-HL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Cutter DJ, Ramroth J, Diez P, et al. Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma. J Clin Oncol. 2021. PMID: 34388007. doi:10.1200/JCO.21.00408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。